

6-Oct-2019


Feb-1 Apr-1 Jun-1

#### Mutual Fund Sector Matrix | Trading at 40.1% Discount (Last Week: 44.4% Discount)


Compared to last week, price to NAV (P/NAV) of the mutual fund increased and stood at 0.6x this week. Among the nine fund managers with closed end funds, RACE had the highest YTD NAV return (0.4%). First Bangladesh Fixed Income Fund (Fund Manager: RACE) was traded at highest discount (63.0%), whereas Prime Finance First Mutual Fund (Fund Manager: ICB AMCL) was traded at highest price to NAV (169.0%). In last 52 weeks, Asian Tiger Sandhani Life Growth Fund (Fund Manager: ASIAN TIGER) outperformed the market 26 times. Popular Life First Mutual Fund had the highest Sharpe ratio.

#### **Asset Managers' Statistics**

| # | Fund<br>Manager | No. of<br>Funds | AUM**<br>(BDT mn) | AUM (USD<br>mn) | Mkt Cap<br>(BDT mn) | Mkt Cap<br>(USD mn) | Price to<br>NAV(x) |        | Dividend<br>Yield (%) | YTD NAV<br>Return<br>(%) | Adjusted<br>YTD NAV<br>Return<br>(%)*** | DSEX<br>Return<br>(%)* |
|---|-----------------|-----------------|-------------------|-----------------|---------------------|---------------------|--------------------|--------|-----------------------|--------------------------|---|------------------------|
| 1 | RACE            | 10              | 30,090            | 356             | 12,223              | 145                 | 0.41               | (59.4) | 7.3                   | 0.4                      | 3.4                                     | (0.8)                  |
| 2 | SEML            | 3               | 2,229             | 26              | 2,878               | 34                  | 1.29               | 29.1   | 3.9                   | (3.5)                    | 1.3                                     | (0.8)                  |
| 3 | lr global       | 6               | 9,125             | 108             | 6,515               | 77                  | 0.71               | (28.6) | 9.4                   | (5.8)                    | 0.5                                     | (0.8)                  |
| 4 | VIPB            | 2               | 1,973             | 23              | 1,617               | 19                  | 0.82               | (18.1) | 11.5                  | (6.1)                    | 2.8                                     | (0.8)                  |
| 5 | AIMS            | 2               | 3,945             | 47              | 2,685               | 32                  | 0.68               | (32.0) | 8.4                   | (8.2)                    | (2.9)                                   | (0.8)                  |
| 6 | ASIAN TIGER     | 1               | 724               | 9               | 599                 | 7                   | 0.83               | (17.2) | 7.7                   | (8.9)                    | (3.1)                                   | (0.8)                  |
| 7 | VAML            | 2               | 2,555             | 30              | 1,810               | 21                  | 0.71               | (29.2) | 7.3                   | (11.3)                   | (6.8)                                   | (0.8)                  |
| 8 | CAPM            | 2               | 1,104             | 13              | 1,210               | 14                  | 1.10               | 9.6    | 6.5                   | (11.5)                   | (5.2)                                   | (0.8)                  |
| 9 | ICB AMCL        | 9               | 5,189             | 61              | 4,555               | 54                  | 0.88               | (12.2) | 8.3                   | (12.7)                   | (6.3)                                   | (0.8)                  |
|   | Total           | 37              | 56,934            | 674             | 34,091              | 403                 | 0.60               | (40.1) | 7.8                   | (3.9)                    | 0.6                                     | (0.8)                  |



#### Fund's Trading at Lowest to Highest P/NAV



Please see penultimate page for additional important disclosures. Unicap Securities Ltd. ("UNICAP") is a foreign broker-dealer unregistered in the USA. UNICAP research is prepared by research analysts who are not registered in the USA. UNICAP research is distributed in the USA pursuant to Rule 15a -6 of the Securities Exchange Act of 1934 solely by Rosenblatt Securities Inc., an SEC registered and FINRA-member broker-dealer



## **Weekly Mutual Fund Review**

6-Oct-2019

Treynor Ratio

(%)

5.49

4.33

2.57

1.80

1.28

## **Proximity to Redemption**

## **Ranking Based on Different Performance Parameters**

| <b>EXIM1STMF</b>  | 5012 |
|-------------------|------|
| FBFIF             | 4521 |
| ABB1STMF          | 4479 |
| LRGLOBMF1         | 4365 |
| EBLNRBMF          | 4239 |
| <b>AIBL1STIMF</b> | 4113 |
| PHPMF1            | 4067 |
| POPULAR1MF        | 4030 |
| GREENDELMF        | 4009 |
| 1 JANATAMF        | 4001 |
| IFIC1STMF         | 3829 |
| <b>DBH1STMF</b>   | 3776 |
| TRUSTB1MF         | 3765 |
| ICBAMCL2ND        | 3672 |
| <b>EBL1STMF</b>   | 3604 |
| <b>1STPRIMFMF</b> | 3447 |
| CAPMIBBLMF        | 3073 |
| ICBAGRANI1        | 2917 |
| CAPMBDBLMF        | 2644 |
| SEMLIBBLSF        | 2644 |
| VAMLRBBF          | 2613 |
| VAMLBDMF1         | 2187 |
| SEMLLECMF         | 2187 |
| GRAMEENS2         | 1395 |
| ICBSONALI1        | 1334 |
| NCCBLMF1          | 938  |
| <b>NLI1STMF</b>   | 849  |
| <b>RELIANCE1</b>  | 634  |
| SEBL1STMF         | 573  |
| ATCSLGF           | 543  |
| <b>MBL1STMF</b>   | 484  |
| IFILISLMF1        | 392  |
| <b>ICB3RDNRB</b>  | 208  |
| <b>PF1STMF</b>    | 208  |
| PRIME1ICBA        | 87   |
|                   |      |

| Rank | Ticker     | Sharpe Ratio<br>(%) | Rank | Ticker           |
|------|------------|---------------------|------|------------------|
| 1    | POPULAR1MF | 0.02                | 1    | AIBL1STIMF       |
| 2    | EXIM1STMF  | (0.00)              | 2    | NCCBLMF1         |
| 3    | IFIC1STMF  | (0.01)              | 3    | <b>ICB3RDNRB</b> |
| 4    | PHPMF1     | (0.01)              | 4    | ICBEPMF1S1       |
| 5    | GRAMEENS2  | (0.02)              | 5    | <b>PF1STMF</b>   |

| Rank | Ticker      | Excess Return<br>(%) |
|------|-------------|----------------------|
| 1    | ABBISTMF    | 2.14                 |
| 2    | EBL1STMF    | 1.69                 |
| 3    | 1 STPRIMFMF | 1.11                 |
| 4    | TRUSTB1MF   | 1.00                 |
| 5    | ATCSLGF     | 0.87                 |

| Rank | Ticker     | NAV Return<br>(%) |
|------|------------|-------------------|
| 1    | ABB1STMF   | 1.52              |
| 2    | EBL1STMF   | 1.07              |
| 3    | 1STPRIMFMF | 0.92              |
| 4    | ICBAMCL2ND | 0.40              |
| 5    | TRUSTB1MF  | 0.38              |

| Rank | Ticker    | YTD NAV Return<br>(%) |
|------|-----------|-----------------------|
| 1    | LRGLOBMF1 | (1.22)                |
| 2    | PHPMF1    | (4.17)                |
| 3    | EBLNRBMF  | (4.25)                |
| 4    | FBFIF     | (4.65)                |
| 5    | IFIC1STMF | (4.85)                |


| R | ank | Ticker     | Dividend Yield<br>(%) |
|---|-----|------------|-----------------------|
|   | 1   | MBL1STMF   | 11.76                 |
|   | 2   | SEBL1STMF  | 11.65                 |
|   | 3   | AIBL1STIMF | 11.59                 |
|   | 4   | RELIANCE1  | 11.36                 |
|   | 5   | NLI1STMF   | 11.11                 |

Days

ICBEPMF1S1

## Number of Weeks a Fund Outperformed the Market in Last 52 Weeks

.





# Weekly Mutual Fund Review

6-Oct-2019

#### **Closed End Fund's Statistics**

| #  | Ticker            | AUM (BDT<br>mn) | No. of Units<br>(mn) | Fund<br>Manager | Year<br>End | NAV at<br>Market<br>(BDT) | NAV at<br>Cost<br>(BDT) | Cash Div<br>(%) | RIU (%) | Redemption<br>Date |
|----|-------------------|-----------------|----------------------|-----------------|-------------|---------------------------|-------------------------|-----------------|---------|--------------------|
| 1  | 1 JANATAMF        | 3,019           | 290                  | RACE            | Jun         | 10.41                     | 11.08                   | 3.0             | -       | 19-Sep-2030        |
| 2  | 1STPRIMFMF        | 197             | 20                   | ICB AMCL        | Dec         | 9.86                      | 17.79                   | 8.5             | -       | 14-Mar-2029        |
| 3  | ABBISTMF          | 2,553           | 239                  | RACE            | Jun         | 10.68                     | 11.34                   | 3.0             | -       | 10-Jan-2032        |
| 4  | AIBL1STIMF        | 1,019           | 100                  | LR GLOBAL       | Mar         | 10.19                     | 10.13                   | 8.0             | -       | 9-Jan-2031         |
| 5  | ATCSLGF           | 724             | 62                   | ASIAN TIGER     | Jun         | 11.71                     | 11.65                   | 7.5             | -       | 1-Apr-2021         |
| 6  | <b>DBH1STMF</b>   | 1,202           | 120                  | LR GLOBAL       | Jun         | 10.01                     | 10.12                   | 8.0             | -       | 6-Feb-2030         |
| 7  | EBL1STMF          | 1,500           | 145                  | RACE            | Jun         | 10.36                     | 10.75                   | 3.0             | -       | 18-Aug-2029        |
| 8  | EBLNRBMF          | 2,326           | 224                  | RACE            | Jun         | 10.37                     | 10.74                   | 3.0             | -       | 15-May-2031        |
| 9  | <b>EXIM1STMF</b>  | 1,489           | 143                  | RACE            | Jun         | 10.39                     | 10.82                   | 3.5             | -       | 26-Jun-2033        |
| 10 | FBFIF             | 8,109           | 776                  | RACE            | Jun         | 10.45                     | 10.71                   | 3.0             | -       | 21-Feb-2032        |
| 11 | GRAMEENS2         | 3,227           | 182                  | AIMS            | Jun         | 17.69                     | 10.58                   | 9.0             | -       | 1-Aug-2023         |
| 12 | GREENDELMF        | 1,490           | 150                  | LR GLOBAL       | Jun         | 9.93                      | 10.01                   | 8.0             | -       | 27-Sep-2030        |
| 13 | <b>ICB3RDNRB</b>  | 653             | 100                  | ICB AMCL        | Jun         | 6.53                      | 11.57                   | 4.0             | -       | 1-May-2020         |
| 14 | ICBAMCL2ND        | 373             | 50                   | ICB AMCL        | Jun         | 7.45                      | 13.39                   | 6.0             | -       | 25-Oct-2029        |
| 15 | ICBEPMF1S1        | 479             | 75                   | ICB AMCL        | Jun         | 6.38                      | 11.70                   | 4.5             | -       | 1-Jan-2019         |
| 16 | ICBSONALI1        | 790             | 100                  | ICB AMCL        | Jun         | 7.90                      | 11.11                   | 6.0             | -       | 1-Jun-2023         |
| 17 | IFIC1STMF         | 1,892           | 182                  | RACE            | Jun         | 10.39                     | 10.87                   | 3.0             | -       | 31-Mar-2030        |
| 18 | IFILISLMF1        | 745             | 100                  | ICB AMCL        | Jun         | 7.45                      | 10.97                   | 6.0             | -       | 1-Nov-2020         |
| 19 | LRGLOBMF1         | 3,280           | 311                  | LR GLOBAL       | Sep         | 10.54                     | 10.46                   | 5.5             | -       | 18-Sep-2031        |
| 20 | MBL1STMF          | 1,024           | 100                  | LR GLOBAL       | Mar         | 10.24                     | 9.75                    | 8.0             | -       | 1-Feb-2021         |
| 21 | NCCBLMF1          | 1,110           | 109                  | LR GLOBAL       | Dec         | 10.23                     | 10.17                   | 6.0             | -       | 1-May-2022         |
| 22 | NLI1STMF          | 691             | 50                   | VIPB            | Jun         | 13.72                     | 12.29                   | 13.0            | -       | 1-Feb-2022         |
| 23 | PF1STMF           | 405             | 60                   | ICB AMCL        | Jun         | 6.75                      | 11.77                   | 5.0             | -       | 1-May-2020         |
| 24 | PHPMF1            | 2,911           | 282                  | RACE            | Jun         | 10.33                     | 10.72                   | 3.0             | -       | 24-Nov-2030        |
| 25 | POPULAR1MF        | 3,118           | 299                  | RACE            | Jun         | 10.43                     | 10.93                   | 3.0             | -       | 18-Oct-2030        |
| 26 | <b>PRIME1ICBA</b> | 718             | 100                  | ICB AMCL        | Jun         | 7.18                      | 11.62                   | 6.0             | -       | 1-Jan-2020         |
| 27 | RELIANCE1         | 718             | 60                   | AIMS            | Jun         | 11.88                     | 10.80                   | 10.0            | -       | 1-Jul-2021         |
| 28 | SEBLISTMF         | 1,282           | 100                  | VIPB            | Jun         | 12.85                     | 11.53                   | 12.0            | -       | 1-May-2021         |
| 29 | Semllecmf         | 492             | 50                   | SEML            | Jun         | 9.85                      | 11.13                   | 5.0             | -       | 1-Oct-2025         |
| 30 | TRUSTB1MF         | 3,172           | 304                  | RACE            | Jun         | 10.45                     | 10.98                   | 3.5             | -       | 26-Jan-2030        |
| 31 | VAMLBDMF1         | 1,058           | 104                  | VAML            | Sep         | 10.14                     | 11.13                   | 5.0             | -       | 1-Oct-2025         |
| 32 | VAMLRBBF          | 1,498           | 159                  | VAML            | Dec         | 9.43                      | 11.32                   | 5.0             | -       | 1-Dec-2026         |
| 33 | CAPMBDBLMF        | 459             | 50                   | САРМ            | Jun         | 9.16                      | 10.80                   | 5.0             | -       | 1-Jan-2027         |
| 34 | SEMLIBBLSF        | 986             | 100                  | SEML            | Jun         | 9.86                      | 10.74                   | 5.0             | -       | 1-Jan-2027         |
| 35 | ICBAGRANI1        | 830             | 98                   | ICB AMCL        | Jun         | 8.45                      | 10.70                   | 5.0             | -       | 1-Oct-2027         |
| 36 | CAPMIBBLMF        | 644             | 67                   | CAPM            | Jun         | 9.64                      | 10.70                   | 8.0             | -       | 5-Mar-28           |



## Annotations:

Sharpe ratio is the fund's average return over the risk free rate divided by the standard deviation of the fund.

**Treynor ratio** is the fund's average return over the risk free rate divided by the beta of the fund. Here the two year treasury bond's cut of yield (converted into weekly basis) is used as a proxy for the risk free rate.

One Week Excess Return is the fund's NAV return in the latest week over the contemporanious weekly return of DSEX.

YTD (Year to Date) NAV Return is the fund's NAV return since the begining of the year to the date of estimation.

Risk Free Rate is value weighted average of cut off yields of 7 - day BB Bill over last one year horizon.

\*\* ICB2NDNRB fund completed tenure on 23 July 2018. NAV was BDT 1,098mn and BDT 1,190mn on 23 July 2018 and 1 January 2018 respectively. In calculating YTD NAV return of mutual fund sector, we excluded the performance of ICB2NDNRB.



#### **Disclaimer**

#### **GENERAL DISCLOSURES**

This research report was prepared by UniCap Securities Ltd. (UNICAP), a company authorized to engage in securities activities in Bangladesh. UNICAP is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

NOTICE TO RECIPIENTS: This email (including all attachments) is intended only for the named recipient. If you have received this email in error, please delete the email plus any copies of it and immediately notify the sender by return email.

The information contained herein has been prepared and issued by UNICAP to its clients, and all intellectual property relating to the Research vests with UNICAP unless otherwise noted. The Research is provided on an as is basis, without warranty (express or implied).

The Research is based on public data obtained in good faith from sources believed by UNICAP be reliable, but no representations, guarantees or warranties are made by UNICAP with regard to accuracy, completeness or suitability of the data and under no circumstances will any of UNICAP, its officers, representatives, associates or agents be liable for any loss or damage, whether direct, incidental or consequential, caused by reliance on or use of the content. UNICAP has not performed any independent review or due diligence of publicly available information. The opinions and estimates contained herein reflect the current judgment of the analyst(s) on the date of this Research and are subject to change without notice. The opinions do not necessarily correspond to the opinions of UNICAP. UNICAP does not have an obligation to update, modify or/(and) amend this Research or otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or/(and) estimate set forth herein, changes or subsequently becomes inaccurate.

This Research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is intended to be distributed in its entirety. It does not constitute a personal recommendation or takes into account the particular investment objectives, financial situations, or needs of individual investors. Investors should consider whether any advice or recommendation in this Research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice and ensure they obtain, read and understand any applicable offer document. The price and value of investments referred to herein and the income from them may fluctuate. Past performance is not an indicator or guarantee of future returns, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this Research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this Research. Neither UNI-CAP nor its representatives, will receive (directly or indirectly) any commission, fee, benefit or advantage, pecuniary or otherwise, nor be influenced, either directly or indirectly, in connection with the making of any recommendation or preparation of any Research.

The analysts named in this report may have from time to time discussed with our clients, including UNICAP salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analysts' published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analysts' fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage group as described herein.

Any prices provided herein (other than those that are identified as being historical) are indicative only, and do not represent firm quotes as to either size or price. The past performance of financial instruments is not indicative of future results. No assurance can be given that any financial instrument or issuer described herein would yield favorable investment results. Any forecasts or price targets shown for companies and/or securities discussed in this Research may not be achieved due to multiple risk factors including without limitation market volatility, sector volatility, corporate actions, the unavailability of complete and accurate information and/or the subsequent transpiration that underlying assumptions made by UNICAP or by other sources relied upon in the Research were inapposite.

UNICAP may provide hyperlinks to websites of entities mentioned in this Research, however the inclusion of a link does not imply that UNICAP endorses, recommends or approves any material on the linked page or accessible from it. UNICAP does not accept responsibility whatsoever for any such material, nor for any consequences of its use.

This document is for the use of the addressees only and may not be reproduced, redistributed or passed on to any other person or published, in whole or in part, for any purpose, without the prior, written consent of UNICAP. The manner of distributing this document may be restricted by law or regulation in certain countries, including the United States. Persons into whose possession this document may come are required to inform themselves about and to observe such restrictions. By accepting this document, a recipient hereof agrees to be bound by the foregoing limitations.

#### **IMPORTANT DISCLOSURES FOR U.S. PERSONS**

This research report was prepared by UniCap Securities Ltd. ("UNICAP"), a company authorized to engage in securities activities in Bangladesh. UNICAP is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Rosenblatt Securities Inc, 40 Wall Street 59th Floor, New York, NY 10005, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UNICAP. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

#### **Ownership and Material Conflicts of Interest**

Rosenblatt Securities Inc. or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Rosenblatt Securities Inc, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Rosenblatt Securities Inc, is not aware of any material conflict of interest as of the date of this publication



#### **Compensation and Investment Banking Activities**

Rosenblatt Securities Inc. or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

#### Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither UNICAP nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inac curacy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

UNICAP may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of UNICAP.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by UNICAP with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of UNICAP and UNICAP accepts no liability whatsoever for the actions of third parties in this respect.

#### EQUITY RECOMMENDATION STRUCTURE (ABSOLUTE RATINGS)

We calculate our target price by weighting DCF, DDM, SOTP, asset-based and other relative valuation methods, and applying appropriate premiums/ discounts and/or other relevant adjustments.

Expected absolute returns are calculated as the percentage of difference between our target price and latest close price. Stock recommendations are based on absolute upside (downside) and have a 12-month horizon. Please note that future price fluctuations could lead to a temporary mismatch between upside/downside for a stock and our recommendation.

| Recommendation | Rating | Expected absolute returns (%) over 12 months |
|----------------|--------|--|
|                | A+     | More than 25%                                |
| BUY            | A      | Between 20% and 25%                          |
|                | A-     | Between 15% and 20%                          |
|                | B+     | Between 10% and 15%                          |
| HOLD           | В      | Between 5% and 10%                           |
|                | В-     | Between 0% and 5%                            |
|                | C+     | Between 0% and -5%                           |
| SELL           | С      | Between -5% and -10%                         |
|                | C-     | Less than -10%                               |

#### ANALYST CERTIFICATION

Respective analyst(s) identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. The research analyst(s) named on this report are not registered / qualified as research analysts with FINRA.

It has not been determined in advance whether and in what intervals this document will be updated. Unless otherwise stated current prices refer to the most recent trading day's closing price.



## **Contact Us**

## **Research Team**

| Sadat M Faisal | Research In-Charge | sadat@unicap-securities.com  | +880 1755 694 029 |
|----------------|--------------------|------------------------------|-------------------|
| Fahim Hassan   | Research Analyst   | fahim@unicap-securities.com  | +880 1701 220 128 |
| Protik Dey     | Research Analyst   | protik@unicap-securities.com | +880 1701 220 127 |

## Institutional & International Sales & Trading

| Kamal Krishna Saha, CFA | Head of Institutional Sales & Trading     | kamal@unicap-securities.com   | +880 1701 220 109 |
|-------------------------|---|-------------------------------|-------------------|
| Sabina Yesmin           | Relationship Manager, Institutional Sales | sabina@unicap-securities.com  | +880 1755 694 038 |
| Md. Mustafa Kamal       | Deputy Manager, Institutional Trading     | mustafa@unicap-securities.com | +880 1755 694 035 |
| Mehedi Hasan Niloy      | Business Analyst, Institutional Sales     | niloy@unicap-securities.com   | +880 1755 694 033 |

## Find Us

| Corporate Office                            | Gulshan Office                 | Extension Office                            |
|---|--------------------------------|---|
| A.A Bhaban (9th Floor)                      | Richmond Concord (6th Floor)   | Kazi Tower (5th Floor)                      |
| 23 Motijheel C/A                            | 68 Gulshan Avenue              | 86, Naya Paltan                             |
| Dhaka- 1000                                 | Gulshan- 1, Dhaka- 1212.       | Dhaka- 1000                                 |
| Tel: +880 (2) 9515952 -53, +880 (2) 9515955 | Tel: +880 (2) 8820366, 8828196 | Tel: +880 (2) 933638, 9334749, 9334750      |
| Fax: +880 (2) 9514923                       | Fax: +880 (2) 8825740.         | Fax: +880 (2) 9334750                       |
| Sonargaon Road Branch                       | Chittagong Branch              | Sylhet Branch                               |
| Noor Tower (4th Floor)                      | Ayub Trade Centre (7th Floor)  | J.R Tower (2nd Floor), 23 Abash, Jail Road, |
| 73 Sonargaon Road                           | 1269/B Sk. Mujib Road          | Sylhet-3100                                 |

73 Sonargaon Road Dhaka- 1205. Tel: +880 (2) 9632161 Fax: +880 (2) 9632163 Chittagong Branch Ayub Trade Centre (7th Floor 1269/B Sk. Mujib Road Agrabad, Chittagong- 4100. Tel: +880 (31) 2513558 – 59 Fax: +880 (31) 2513356

J.R Tower (2nd Floor), 23 Abash, Jail Road, Sylhet-3100 Tel: +880 (821) 728440 – 41 Fax: +880 (821) 728437.

For any query, please contact us at: research@unicap-securities.com

Find Our Research on BRC and RES @ BLOOMBERG | Our Wire Code – UCS